title: Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases.
abstract: The growth of metastatic prostate cancer cells in the bone involves an intimate interaction between the tumor cells and various elements of the bone microenvironment, resulting in increased rate of bone turnover and rapid tumor growth. The alpha(v)beta3 integrin has been shown to play an important role in tumor growth and angiogenesis, and is known to be critical to osteoclast formation and activity. This study was designed to examine the role of alpha(v)beta3 expressed by cells native to the bone in the growth and pathogenesis of prostate cancer bone metastases. Human prostate cancer cells which do not express alpha(v)beta3 or alpha(IIb)beta3 integrins were injected directly into human bone fragments previously implanted subcutaneously in SCID mice (SCID-human-bone model). At the same time treatment with anti-beta3 antibody fragment (m7E3 F(ab')2) i.p. at 300 microg/dose 3 x per week was initiated and continued for 2 weeks. In this system, m7E3 F(ab')2 only recognizes human bone-derived alpha(v)beta3. Antibody inhibition of alpha(v)beta3 integrin in vivo resulted in a specific reduction in the proportion of antigenically-human blood vessels within tumor-bearing bone implants (from 73.5% +/- 3.93 in controls to 17.74% +/- 5.64 in treated animals). Proliferation of the alpha(v)beta3-negative tumor cells was also reduced, although the overall vessel density was maintained by compensating mouse vasculature. Blockage of human bone-derived alpha(v)beta3 also significantly reduced the recruitment of osteoclasts in response to tumor cells, as well as degradation of calcified bone tissue. Together these observations confirm the importance of alpha(v)beta3 in bone metabolism and angiogenesis, and point to the role of these processes in controlling growth of metastatic prostate cancer cells in the bone.
authors.affiliation: Department of Oncology Research, Centocor, Inc., Malvern, Pennsylvania 19355, USA.
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Nemeth
authors.forename: Michael L
authors.initials: ML
authors.lastname: Cher
authors.forename: Zhao
authors.initials: Z
authors.lastname: Zhou
authors.forename: Chadwick
authors.initials: C
authors.lastname: Mullins
authors.forename: Sunita
authors.initials: S
authors.lastname: Bhagat
authors.forename: Mohit
authors.initials: M
authors.lastname: Trikha
mesh_terms: D000818:Animals; D017209:Apoptosis; D001859:Bone Neoplasms / Q000473:pathology*; D001842:Bone and Bones / Q000378:metabolism*; D002455:Cell Division; D005434:Flow Cytometry; D006801:Humans; D007150:Immunohistochemistry; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors*; D008297:Male; D051379:Mice; D016513:Mice, SCID; D008856:Microscopy, Fluorescence; D009362:Neoplasm Metastasis; D009389:Neovascularization, Pathologic; D010010:Osteoclasts / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000473:pathology; D014407:Tumor Cells, Cultured
chemical_list: D039302:Integrin alphaVbeta3